top of page

Our lead candidates

Our product development programs are based on two cornerstones: [1] medical need first, technology second, and [2] use patents are nice-to-have, product patents are critical

GLCP-003-1

Cardiovascular

heart.jpg

Reformulation and development of an oral extended-release formulation of a known compound for the treatment of VT/VF and LQTS 

Market size (TAM): EUR76M to EUR455M

GLCP-046-1

Cardiovascular (stroke)

stroke.jpg

Repurposing and development of an oral formulation of a known compound for neuroprotection of stroke-induced brain damage, with a focus on rapid administration

Market size (TAM): EUR171M to EUR1.8B

GLCP-079-1

Infectious Diseases

abscessus.jpeg

Reformulation and development of high-dose, targeted formulation of a known compound for the treatment of drug-resistant M. abscessus infection

Market size (TAM): EUR179M to EUR1.7B

GLCP-009-1

Oncology

onco.webp

Reformulation and development of a target release formulation of a known compound for the treatment of peritoneal cancer

Market size (TAM): EUR50M to EUR100M

GLCP-108-1

Infectious diseases

asper.webp

Reformulation and development of a known compound for the treatment of Aspergillus infections

Market size (TAM): depending on clinical positioning

GLCP-013-1

Oncology

onco.webp

Development of an oral fixed dose combination of two known compounds for the treatment of castrate-resistant prostate cancer (CRPC)

Market size (TAM): depending on clinical positioning

GLCP-008-1

Central Nervous Diseases

brain.webp

Reformulation and development of a high-concentration intramuscular (IM) formulation of a known compound the treatment of Treatment-Resistant Schizophrenia (TRS)

Market size (TAM): EUR73M

GLCP-051-1

Women's Health

endometriosis2.jpg

Reformulation and development of a target and sustained (once-monthly) release formulation of known compound for the treatment of endometriosis and related diseases

Market size (TAM): EUR2B+

GLCP-086-1

Cardiovascular (stroke)

stroke.jpg

Development of a novel formulation of a known compound for neuroprotection of ischemic stroke-induced brain damage in MCA stroke patients undergoing thrombectomy

Market size (TAM): EUR549M to EUR1.1B

GLCP-048-1

Cardiovascular (stroke)

stroke.jpg

Repurposing and development of an oral formulation of a known compound for the prevention of secondary stroke in high-risk patients, with low-bleeding risk and a novel mechanism of action

Market size (TAM): EUR555M to EUR3.2B

GLCP-007-1

Gastro-intestinal disease

gastro.jpg

Development of targeted, extended release formulation of a known compound for the treatment of gastro-intestinal related infections

Market size (TAM): depending on clinical positioning

Science Lab

Strong focus on product innovation

Most of our value-added medicine (VAM) development programs originate from collaborations with prestigious universities, medical schools and smaller specialty pharma firms. In recent years, drug repurposing has indeed gained substantial traction due to its budget constraints and expedited development timelines, particularly compared to new NCE or biotech product development. However, reliance only on existing, commercially available dosage forms presents challenges, as protection through 'use patents' is rather limited. By incorporating a drug reformulation strategy, Galenicap unlocks the potential to create unique products with a robust intellectual property (IP) position that aligns perfectly with the new therapeutic indications being targeted.

Multidisciplinary screening process

Before embarking on new development programs, candidate projects undergo a thorough evaluation process. This includes the validation of clinical necessity and Target Product Profile, an assessment of technical feasibility, scrutiny of the IP landscape and market exclusivity, examination of the regulatory pathway, formulation of an appropriate go-to-market strategy, and exploration of opportunities for commercialization or partnerships. This comprehensive procedure involves close collaboration with external experts and insights from clinical KOLs. Furthermore, the evaluation process takes into account factors such as development costs, portfolio diversification, and a strong emphasis on addressing unmet clinical needs. The objective is to efficiently advance products, maintain a well-balanced portfolio, and prioritize impactful contributions to healthcare.

Friendly Young Doctor_edited.jpg
bottom of page